Should phenytoin and carbamazepine be avoided in Asian populations with the HLA-B*1502 positive genetic variant?

Archives of Disease in Childhood

Volumn 96, Issue 1, 2011, Pages 104-106

  Ganesan, Subramanian ^a   Hussain, Nahin ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN; PHENYTOIN; ANTICONVULSIVE AGENT; HLA B*1502, HUMAN; HLA-B*1502, HUMAN;

ALLELE; ASIAN; EPILEPSY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STEVENS JOHNSON SYNDROME; CHILD; DRUG CONTRAINDICATION; DRUG ERUPTION; ETHNOLOGY; EVIDENCE BASED MEDICINE; GENETICS; REVIEW;

ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; CHILD; DRUG ERUPTIONS; EPILEPSY; EVIDENCE-BASED MEDICINE; HLA-B ANTIGENS; HUMANS; PHENYTOIN;

EID: 78650809147     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.190454     Document Type: Note

References (12)

1. Drug Safety Update. Monthly newsletter from Medicines and Healthcare products Regulatory Agency (MHRA) and UK Commission on Human Medicines, January 2010;3:6.
2. Ferrell PB Jr, McLeod HL . Carbamazepine, HLA-B*1502 and risk of Steven-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9:1543-6.
3. Yoong M, Chin RF, Scott RC. Management of convulsive status epilepticus in children. Arch Dis Child Educ Pract Ed 2009;94:1-9.
4. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-6. (Pubitemid 27368898)
5. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999;353:2190-4.
6. Lim KS, Kwan P, Tan CT. Association of HLA-B*1502 allele and Carbamazepine induced severe adverse cutaneous drug reaction among Asians, a review. Neurol Asia 2008;13:15-21.
7. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009;123:e297-304.
8. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-18.
9. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
10. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087-91.
11. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome.: ethnicity matters. Pharmacogenomics J 2006;6:265-8.
12. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010;51:926-30.